AHK-Cu (Alanine-Histidine-Lysine Copper) vs NAD+
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
AHK-Cu (Alanine-Histidine-Lysine Copper)
Copper-chelating tripeptide structurally related to GHK-Cu but optimized for scalp and hair follicle applications. AHK-Cu activates hair follicle stem cells and prolongs the anagen (active growth) phase, making it a key research compound for androgenetic alopecia and diffuse hair loss. Used topically as an alternative or complement to minoxidil and finasteride.
Full profileNAD+
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme essential to cellular metabolism, DNA repair, and mitochondrial function. Levels decline with age. Research focuses on restoring NAD+ through precursors (NMN, NR) or direct IV/subcutaneous administration to support longevity and energy metabolism.
Full profile| AHK-Cu (Alanine-Histidine-Lysine Copper) | NAD+ | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | AHK copper peptide, Ala-His-Lys copper, hair growth copper peptide, AHK-copper complex | Nicotinamide Adenine Dinucleotide, NAD, NAD+ precursor |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 0.1%–1% %, Daily topical application (scalp) | 250mg–1000mg mg, daily (oral precursors) or weekly/monthly (IV/SubQ) |
| Administration | Topical (scalp serum/solution), Subcutaneous (microneedling-assisted delivery) | Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal |
| Key side effects | Mild scalp irritation, Contact dermatitis (rare), Temporary scalp redness or tingling, Transient scalp shedding at initiation (shedding phase) | Flushing (especially IV), Chest tightness during rapid IV infusion, Nausea, Fatigue (transient, day of infusion) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: AHK-Cu (Alanine-Histidine-Lysine Copper) is research-stage, while NAD+ is preclinical only.
- Administration: AHK-Cu (Alanine-Histidine-Lysine Copper) — Topical (scalp serum/solution), Subcutaneous (microneedling-assisted delivery); NAD+ — Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal.
- Dosing units differ: AHK-Cu (Alanine-Histidine-Lysine Copper) is dosed in %, NAD+ in mg — they operate at different scales.
- Frequency: AHK-Cu (Alanine-Histidine-Lysine Copper) is typically Daily topical application (scalp); NAD+ is daily (oral precursors) or weekly/monthly (IV/SubQ).
How each works
AHK-Cu (Alanine-Histidine-Lysine Copper)
AHK-Cu activates β-catenin/Wnt signaling in dermal papilla cells and promotes VEGF expression around hair follicles. Studies demonstrate extended anagen phase duration, increased follicle size, and upregulation of hair growth factors in treated scalp tissue. The copper component supports tyrosinase activity for follicle pigmentation and metalloenzymes involved in extracellular matrix remodeling around follicles.
NAD+
NAD+ is required for over 500 enzymatic reactions including those catalyzed by sirtuins (longevity-associated proteins) and PARPs (DNA repair enzymes). Rodent studies consistently show that restoring NAD+ levels reverses aspects of metabolic aging. Human trials with NAD+ precursors (NMN, NR) show improved muscle function, insulin sensitivity, and mitochondrial capacity in older adults.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.